Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD/MAD study of ANX1502 in healthy volunteers
NL-OMON53926Phase 1Completed
- Sponsor
- Annexon Biosciences
- Start
- May 2022
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in autoantibody mediated diseases comparing ANX1502 with Matching placebo (2 arms). Primary endpoints: Safety and tolerability after single ascending doses and Safety and tolerability after multiple ascending doses. Started May 2022; status: completed.
02
Drugs
ANX1502
03
Conditions
autoantibody mediated diseases
Beyond the preview
Go deeper on NL-OMON53926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53926.